BR0113491A - Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente. - Google Patents
Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.Info
- Publication number
- BR0113491A BR0113491A BR0113491-4A BR0113491A BR0113491A BR 0113491 A BR0113491 A BR 0113491A BR 0113491 A BR0113491 A BR 0113491A BR 0113491 A BR0113491 A BR 0113491A
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- isolated
- cells
- methods
- specific
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 210000004027 cell Anatomy 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 102000040430 polynucleotide Human genes 0.000 title abstract 3
- 108091033319 polynucleotide Proteins 0.000 title abstract 3
- 239000002157 polynucleotide Substances 0.000 title abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 239000013604 expression vector Substances 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- -1 host cell Proteins 0.000 title abstract 2
- 230000004936 stimulating effect Effects 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 206010009944 Colon cancer Diseases 0.000 abstract 4
- 206010006187 Breast cancer Diseases 0.000 abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 2
- 210000001072 colon Anatomy 0.000 abstract 2
- 208000029742 colonic neoplasm Diseases 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 210000004072 lung Anatomy 0.000 abstract 2
- 201000005202 lung cancer Diseases 0.000 abstract 2
- 208000020816 lung neoplasm Diseases 0.000 abstract 2
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
"POLINUCLEOTìDEO E POLIPEPTìDEO ISOLADOS, VETOR DE EXPRESSãO, CéLULA HOSPEDEIRA, PROTEìNA DE FUSãO, MéTODOS PARA ESTIMULAR E/OU EXPANDIR CéLULAS T ESPECìFICAS PARA UMA PROTEìNA DE TUMOR, PARA ESTIMULAR UMA RESPOSTA IMUNE EM UM PACIENTE, PARA O TRATAMENTO DE UM CâNCER EM UM PACIENTE E PARA INIBIR O DESENVOLVIMENTO DE UM CâNCER EM UM PACIENTE POPULAçãO DE CéLULA T ISOLADA, COMPOSIçãO, E, USO DE UM COMPONENTE". Composições e métodos para a terapia e diagnóstico do câncer, particularmente câncer pulmonar, de cólon, colorretal e de mama, são divulgados. As composições ilustrativas compreendem um ou mais polipeptídeos de tumor Cripto, porções imunogênicas destes, polinucleotídeos que codificam tais polipeptídeos, célula que apresenta antígeno que expressa tais polipeptídeos e células T que são específicas para as células que expressam tais polipeptídeos. As composições divulgadas são úteis, por exemplo, no diagnóstico, prevenção e/ou tratamento de doenças, particularmente câncer pulmonar, de cólon, colorretal e de mama.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0020953.6A GB0020953D0 (en) | 2000-08-24 | 2000-08-24 | Vaccine |
| PCT/EP2001/009646 WO2002016413A2 (en) | 2000-08-24 | 2001-08-20 | Cripto tumour polypeptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0113491A true BR0113491A (pt) | 2003-06-24 |
Family
ID=9898284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0113491-4A BR0113491A (pt) | 2000-08-24 | 2001-08-20 | Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7439320B2 (pt) |
| EP (1) | EP1311678A2 (pt) |
| JP (1) | JP2004506441A (pt) |
| KR (1) | KR20030045041A (pt) |
| CN (1) | CN1471579A (pt) |
| AR (1) | AR032173A1 (pt) |
| AU (1) | AU2001295498A1 (pt) |
| BR (1) | BR0113491A (pt) |
| CA (1) | CA2420087A1 (pt) |
| CZ (1) | CZ2003537A3 (pt) |
| GB (1) | GB0020953D0 (pt) |
| HU (1) | HUP0302824A2 (pt) |
| IL (1) | IL154533A0 (pt) |
| MX (1) | MXPA03001634A (pt) |
| NO (1) | NO20030823L (pt) |
| NZ (1) | NZ524344A (pt) |
| PL (1) | PL363005A1 (pt) |
| WO (1) | WO2002016413A2 (pt) |
| ZA (1) | ZA200301436B (pt) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR395801A0 (en) * | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
| PT1390389E (pt) | 2001-04-26 | 2009-04-03 | Biogen Idec Inc | Anticorpos que bloqueiam o cripto e as utilizações dos mesmos |
| US7582299B2 (en) | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| US20060194265A1 (en) * | 2001-10-23 | 2006-08-31 | Morris David W | Novel therapeutic targets in cancer |
| JP2005520566A (ja) * | 2002-03-22 | 2005-07-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｃｒｉｐｔｏ特異的抗体 |
| CA2529945A1 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| ES2408704T3 (es) | 2005-01-05 | 2013-06-21 | Biogen Idec Ma Inc. | Moléculas de unión a Cripto |
| US8527510B2 (en) | 2005-05-23 | 2013-09-03 | Monster Worldwide, Inc. | Intelligent job matching system and method |
| US8195657B1 (en) | 2006-01-09 | 2012-06-05 | Monster Worldwide, Inc. | Apparatuses, systems and methods for data entry correlation |
| US8600931B1 (en) | 2006-03-31 | 2013-12-03 | Monster Worldwide, Inc. | Apparatuses, methods and systems for automated online data submission |
| US12314907B2 (en) | 2006-03-31 | 2025-05-27 | Monster Worldwide, Inc. | Apparatuses, methods and systems for automated online data submission |
| AU2007243181A1 (en) * | 2006-04-28 | 2007-11-08 | Biogen Idec Ma Inc. | Composition and methods for the detection of Cripto-3 |
| WO2008040759A1 (en) * | 2006-10-03 | 2008-04-10 | Pharmexa A/S | Method for down-regulation of cripto |
| US8645817B1 (en) | 2006-12-29 | 2014-02-04 | Monster Worldwide, Inc. | Apparatuses, methods and systems for enhanced posted listing generation and distribution management |
| US8244551B1 (en) | 2008-04-21 | 2012-08-14 | Monster Worldwide, Inc. | Apparatuses, methods and systems for advancement path candidate cloning |
| CA2809819A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
| DK2528625T3 (da) | 2010-04-15 | 2013-10-14 | Spirogen Sarl | Pyrrolobenzodiazepiner og konjugater deraf |
| BR112012030311A2 (pt) | 2010-06-08 | 2017-01-24 | Genentech Inc | anticorpo |
| JP5889912B2 (ja) | 2010-11-17 | 2016-03-22 | ジェネンテック， インコーポレイテッド | アラニニルメイタンシノール抗体コンジュゲート |
| KR101992502B1 (ko) | 2011-05-12 | 2019-06-24 | 제넨테크, 인크. | 프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법 |
| JP6104257B2 (ja) | 2011-10-14 | 2017-03-29 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピンおよびそのコンジュゲート |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| DK2906298T3 (en) | 2012-10-12 | 2018-12-17 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| AU2013328625B2 (en) | 2012-10-12 | 2016-12-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| ES2649990T3 (es) | 2012-10-12 | 2018-01-16 | Medimmune Limited | Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas |
| CN104837502B (zh) | 2012-10-12 | 2018-08-10 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其结合物 |
| EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| US10751346B2 (en) | 2012-10-12 | 2020-08-25 | Medimmune Limited | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates |
| CN105246894A (zh) | 2012-12-21 | 2016-01-13 | 斯皮罗根有限公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| CN105189507A (zh) | 2012-12-21 | 2015-12-23 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂卓及其结合物 |
| CA2905181C (en) | 2013-03-13 | 2020-06-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy |
| SG11201507214SA (en) | 2013-03-13 | 2015-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| NZ710746A (en) | 2013-03-13 | 2018-11-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| EP3033111B1 (en) | 2013-08-12 | 2019-03-13 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| BR112016013258A2 (pt) | 2013-12-16 | 2018-01-16 | Genentech Inc | composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit |
| KR20170042495A (ko) | 2013-12-16 | 2017-04-19 | 제넨테크, 인크. | 펩티드모방체 화합물 및 그의 항체-약물 접합체 |
| JP6671292B2 (ja) | 2013-12-16 | 2020-03-25 | ジェネンテック， インコーポレイテッド | ペプチド模倣化合物及びその抗体−薬物コンジュゲート |
| US20170330153A1 (en) | 2014-05-13 | 2017-11-16 | Monster Worldwide, Inc. | Search Extraction Matching, Draw Attention-Fit Modality, Application Morphing, and Informed Apply Apparatuses, Methods and Systems |
| JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| MX2017003123A (es) | 2014-09-12 | 2017-05-12 | Genentech Inc | Anticuerpos y conjugados modificados geneticamente con cisteina. |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| US20160074527A1 (en) | 2014-09-17 | 2016-03-17 | Genentech, Inc. | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| AU2015352545B2 (en) | 2014-11-25 | 2020-10-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| MX2017007169A (es) | 2014-12-03 | 2018-05-02 | Genentech Inc | Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos. |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CA2996902C (en) | 2015-10-02 | 2020-06-02 | Genentech, Inc. | Pyrrolobenzodiazepine antibody drug conjugates and methods of use |
| EP3362100B1 (en) | 2015-10-16 | 2022-06-22 | Genentech, Inc. | Hindered disulfide drug conjugates |
| EP3365025B1 (en) | 2015-10-20 | 2020-07-15 | Genentech, Inc. | Calicheamicin-antibody-drug conjugates and methods of use |
| US10691773B2 (en) | 2015-12-30 | 2020-06-23 | General Electric Company | Cell processing techniques |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN114028549A (zh) * | 2016-02-19 | 2022-02-11 | 伊玛提克斯生物技术有限公司 | 用于nhl和其他癌症免疫治疗的新型肽和肽组合物 |
| US20170315132A1 (en) | 2016-03-25 | 2017-11-02 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
| EP3465221B1 (en) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
| US10639378B2 (en) | 2016-06-06 | 2020-05-05 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
| WO2018031662A1 (en) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
| EP3522933B1 (en) | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| MX375569B (es) | 2017-02-08 | 2025-03-04 | Adc Therapeutics Sa | Conjugados de pirrolobenzodiazepinas y anticuerpos |
| PT3612537T (pt) | 2017-04-18 | 2022-08-29 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina |
| ES2977788T3 (es) | 2017-04-20 | 2024-08-30 | Adc Therapeutics Sa | Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco |
| MX2019015042A (es) | 2017-06-14 | 2020-08-06 | Adc Therapeutics Sa | Regimen de dosificacion. |
| DK3668874T3 (da) | 2017-08-18 | 2022-02-14 | Medimmune Ltd | Pyrrolobenzodiazepin-konjugater |
| IL273387B2 (en) | 2017-09-20 | 2023-10-01 | Ph Pharma Co Ltd | Thylanstatin analogs |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| JP7708662B2 (ja) | 2018-10-24 | 2025-07-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | コンジュゲート化された化学的分解誘導物質および使用方法 |
| EP3894427A1 (en) | 2018-12-10 | 2021-10-20 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| KR102890251B1 (ko) | 2019-03-15 | 2025-11-25 | 메드임뮨 리미티드 | 암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트 |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| CN117980327A (zh) | 2021-11-03 | 2024-05-03 | 杭州多禧生物科技有限公司 | 抗体的特异性偶联 |
| EP4637833A2 (en) | 2022-12-23 | 2025-10-29 | Genentech, Inc. | Cereblon degrader conjugates, and uses thereof |
| EP4698230A2 (en) | 2023-04-17 | 2026-02-25 | Peak Bio, Inc. | Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates |
| WO2026006688A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Degrader antibody conjugates and uses thereof |
| WO2026006689A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Bcl-xl degrader antibody conjugates and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256643A (en) * | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
| US5264557A (en) * | 1991-08-23 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Polypeptide of a human cripto-related gene, CR-3 |
| US5633147A (en) * | 1994-03-08 | 1997-05-27 | Human Genome Sciences, Inc. | Transforming growth factor αH1 |
| US6270777B1 (en) * | 1996-12-20 | 2001-08-07 | University Technologies International Inc. | Conserved metalloprotease epitopes |
| US5834399A (en) * | 1997-12-22 | 1998-11-10 | Eastman Kodak Company | Subbing layer for dye-donor element used in thermal dye transfer |
| IL125608A0 (en) | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| US6387888B1 (en) * | 1998-09-30 | 2002-05-14 | American Foundation For Biological Research, Inc. | Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen |
| US6537552B1 (en) * | 1999-10-19 | 2003-03-25 | Iowa State University Research Foundation | Vaccine adjuvant |
| EP1358349A2 (en) * | 2000-06-05 | 2003-11-05 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
| AUPR395801A0 (en) | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
| GB0219776D0 (en) * | 2002-08-24 | 2002-10-02 | Oxford Glycosciences Uk Ltd | A protein involved in carcinoma |
-
2000
- 2000-08-24 GB GBGB0020953.6A patent/GB0020953D0/en not_active Ceased
-
2001
- 2001-08-20 US US10/362,597 patent/US7439320B2/en not_active Expired - Fee Related
- 2001-08-20 CN CNA018177336A patent/CN1471579A/zh active Pending
- 2001-08-20 HU HU0302824A patent/HUP0302824A2/hu unknown
- 2001-08-20 JP JP2002521508A patent/JP2004506441A/ja active Pending
- 2001-08-20 PL PL01363005A patent/PL363005A1/xx unknown
- 2001-08-20 AU AU2001295498A patent/AU2001295498A1/en not_active Abandoned
- 2001-08-20 CA CA002420087A patent/CA2420087A1/en not_active Abandoned
- 2001-08-20 EP EP01976131A patent/EP1311678A2/en not_active Withdrawn
- 2001-08-20 MX MXPA03001634A patent/MXPA03001634A/es not_active Application Discontinuation
- 2001-08-20 IL IL15453301A patent/IL154533A0/xx unknown
- 2001-08-20 NZ NZ524344A patent/NZ524344A/en unknown
- 2001-08-20 CZ CZ2003537A patent/CZ2003537A3/cs unknown
- 2001-08-20 WO PCT/EP2001/009646 patent/WO2002016413A2/en not_active Ceased
- 2001-08-20 KR KR10-2003-7002701A patent/KR20030045041A/ko not_active Withdrawn
- 2001-08-20 BR BR0113491-4A patent/BR0113491A/pt not_active IP Right Cessation
- 2001-08-23 AR ARP010104025A patent/AR032173A1/es not_active Application Discontinuation
-
2003
- 2003-02-21 NO NO20030823A patent/NO20030823L/no not_active Application Discontinuation
- 2003-02-21 ZA ZA200301436A patent/ZA200301436B/xx unknown
- 2003-04-04 US US10/407,481 patent/US20040138112A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2420087A1 (en) | 2002-02-28 |
| US20040138112A1 (en) | 2004-07-15 |
| EP1311678A2 (en) | 2003-05-21 |
| KR20030045041A (ko) | 2003-06-09 |
| US20040054142A1 (en) | 2004-03-18 |
| WO2002016413A2 (en) | 2002-02-28 |
| MXPA03001634A (es) | 2004-09-10 |
| WO2002016413A8 (en) | 2003-02-06 |
| PL363005A1 (pl) | 2004-11-15 |
| JP2004506441A (ja) | 2004-03-04 |
| CN1471579A (zh) | 2004-01-28 |
| NO20030823D0 (no) | 2003-02-21 |
| AR032173A1 (es) | 2003-10-29 |
| NO20030823L (no) | 2003-04-23 |
| US7439320B2 (en) | 2008-10-21 |
| HUP0302824A2 (hu) | 2005-05-30 |
| IL154533A0 (en) | 2003-09-17 |
| CZ2003537A3 (cs) | 2003-09-17 |
| WO2002016413A3 (en) | 2002-12-05 |
| AU2001295498A1 (en) | 2002-03-04 |
| NZ524344A (en) | 2004-07-30 |
| GB0020953D0 (en) | 2000-10-11 |
| ZA200301436B (en) | 2004-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0113491A (pt) | Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente. | |
| TR200103560T2 (tr) | Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı | |
| WO2001072295A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| HUP0302532A2 (hu) | Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások | |
| MXPA02000192A (es) | Composiciones y metodos para la terapia y diagnostico de cancer de pulmon. | |
| TW200728465A (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| BR0107643A (pt) | Composições e processos para a terapia e diagnóstico de c ncer de próstata | |
| WO2001092581A3 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| WO2002004514A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| WO2002092001A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| BR0110091A (pt) | Composições e processos para terapia e diagnóstico de câncer de mama | |
| BR9808509A (pt) | Composições e métodos para o tratamento e diagnóstico do câncer de mama | |
| WO2002078516A3 (en) | Compositions and methods for the therapy and diagnosis of cancer | |
| WO2002012328A8 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
| WO2003037267A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| WO2001077168A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| BR0111024A (pt) | Composições e métodos para a terapia e diagnóstico de câncer de mama | |
| WO2003013431A3 (en) | Compositions and methods for the therapy and diagnosis of breast cancer | |
| WO2002039885A3 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| WO2005051990A3 (en) | Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer | |
| WO2003086175A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| WO2002000174A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| EP1351967A4 (en) | COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER | |
| WO2001094409A3 (en) | Compositions and methods for the therapy and diagnosis of pancreatic cancer | |
| WO2001098339A3 (en) | Compositions and methods for the therapy and diagnosis of breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 5A, 6A E 7A ANUIDADE |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008. |